These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 15018597

  • 1. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

  • 2. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 3. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M, Freij A, EXPRESS Study Group.
    J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
    Eriksson BI.
    Thromb Res; 2003 Jul 15; 109 Suppl 1():S23-9. PubMed ID: 12818631
    [Abstract] [Full Text] [Related]

  • 7. Ximelagatran in orthopaedic surgery.
    Eriksson B.
    Pathophysiol Haemost Thromb; 2005 Jul 15; 34 Suppl 1():10-7. PubMed ID: 15812199
    [Abstract] [Full Text] [Related]

  • 8. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
    Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D, Melagatran for Thrombin inhibition in Orthopaedic surgery.
    Lancet; 2002 Nov 09; 360(9344):1441-7. PubMed ID: 12433510
    [Abstract] [Full Text] [Related]

  • 9. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP.
    Am J Health Syst Pharm; 2005 Jul 15; 62(14):1451-67. PubMed ID: 15998925
    [Abstract] [Full Text] [Related]

  • 10. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B.
    Drugs; 2004 Jul 15; 64 Suppl 1():27-35. PubMed ID: 15586625
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug 15; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wählby U, Hamrén B, Gustafsson D, Eriksson BI.
    Clin Pharmacokinet; 2003 Aug 15; 42(7):687-701. PubMed ID: 12844328
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G, AstraZeneca Arthroplasty Study Group.
    Arch Intern Med; 2001 Oct 08; 161(18):2215-21. PubMed ID: 11575978
    [Abstract] [Full Text] [Related]

  • 17. Oral direct thrombin inhibitors in clinical development.
    Gustafsson D.
    J Intern Med; 2003 Oct 08; 254(4):322-34. PubMed ID: 12974871
    [Abstract] [Full Text] [Related]

  • 18. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N.
    Anaesthesia; 2004 Aug 08; 59(8):803-10. PubMed ID: 15270973
    [Abstract] [Full Text] [Related]

  • 19. Ximelagatran.
    Choudhury A, Goyal D, Lip GY.
    Drugs Today (Barc); 2006 Jan 08; 42(1):3-19. PubMed ID: 16511607
    [Abstract] [Full Text] [Related]

  • 20. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
    Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW.
    Ann Intern Med; 2002 Oct 15; 137(8):648-55. PubMed ID: 12379064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.